{"id":"NCT01349790","sponsor":"Octapharma","briefTitle":"Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia","officialTitle":"Prospective, Open-label, Non-controlled, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-10","primaryCompletion":"2013-07","completion":"2013-07","firstPosted":"2011-05-09","resultsPosted":"2017-06-07","lastUpdate":"2017-06-07"},"enrollment":40,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Thrombocytopenia"],"interventions":[{"type":"DRUG","name":"NewGam","otherNames":[]}],"arms":[{"label":"NewGam","type":"EXPERIMENTAL"}],"summary":"NewGam is a newly developed human normal immunoglobulin solution for intravenous administration (IGIV). This study will evaluate the safety and efficacy of NewGam 10% in patients with primary immune thrombocytopenia.","primaryOutcome":{"measure":"Percentage of Responders","timeFrame":"Day 1 to Day 8","effectByArm":[{"arm":"NewGam","deltaMin":80.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":["30687970"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":40},"commonTop":["Headache","Pyrexia","Autoimmune thrombocytopenia","Nausea","Anaemia"]}}